ARIAD Pharmaceuticals, Inc.
ARIAD Pharmaceuticals, Inc. company was founded in 1991 and is based in Cambridge, Massachusetts. ARIAD Pharmaceuticals, Inc. (ARIAD) is a biopharmaceutical company engaged in the discovery and development of medicines to treat cancers by regulating cell signaling with small molecules. The Company’s lead cancer product candidate, deforolimus, is an internally discovered, potent inhibitor of the protein mTOR, a master switch in cancer cells. Blocking mTOR creates a starvation-like effect in cancer cells by interfering with cell growth, division, metabolism and angiogenesis. Its second product candidate, AP24534, is a multi-targeted kinase inhibitor that has potential applications in cancer and is wholly owned by the Company. The company also focused drug discovery program centered on small-molecule therapies, molecularly targeted to cell-signaling pathways implicated in cancer. It also developed a portfolio of cell-signaling regulation technologies, its ARGENT technology, to control intracellular processes with small molecules.
Contact Details
Office Address
ARIAD Pharmaceuticals, Inc.
26 Landsdowne Street
Cambridge, MA, USA 02139-4234
Phone: (617) 494-0400
Fax: (617) 494-8144
Executives
Chairman & Chief Exec. Officer
Dr. Harvey J. Berger
Chief Financial Officer
Mr. Edward M. Fitzgerald
.webp)
.webp)
.webp)
.webp)
.webp)
